相关实验视频
Updated: Jan 11, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
对接和数据库查确定曼尼迪平是慢性病中矩阵金属蛋白酶-7的潜在调节剂
Chia-Te Liao1, Yen-Chung Lin2, Hung-Jin Huang3
1Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, Taiwan.
确定曼尼迪平药物向矩阵金属蛋白酶-7 (MMP7) 并保护慢性病 (CKD). 它通过增强自,抑制炎症细胞和减少纤维化而起作用,为病提供了一种新的治疗方法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 矩阵金属蛋白酶 (MMPs),特别是MMP7,是细胞外矩阵重塑和病病原体的关键.
- 确定慢性病 (CKD) 的向治疗方法至关重要.
研究的目的:
- 发现一种针对MMP7的药物,用于CKD的潜在治疗用途.
- 在体外和体外CKD模型中阐明这种药物的分子机制.
主要方法:
- 使用DrugBank数据库进行虚拟药物查,以识别MMP7抑制剂.
- 在细胞上的体外实验和使用CKD小鼠模型的体内研究来验证药物效应.
- 评估了MMP7活性,自,炎症酶激活,纤维化标志物,功能和结构.
主要成果:
- 曼尼迪平被确定为一种降低MMP7活性的潜在候选药物.
- 曼尼迪平增强了自和抑制了细胞中的NLRP3/NLRP6炎症酶激活.
- 在CKD模型中,曼尼迪平治疗降低了纤维化相关蛋白质的调节,降低了纤维化,改善了功能,并减轻了损伤.
结论:
- 曼尼迪平通过调节MMP7活性,自,炎症体和纤维化,在CKD中表现出脏保护作用.
- 这些发现表明曼尼迪平在减轻CKD进展方面具有一种新的治疗机制.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
06:38Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease I: Introduction
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System